News & Events

Press Releases

Jan 10

Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates

- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced muscle tropism and microdystrophin expression - - Company enters 2022 with approximately $210 million in

Read More
Jan 06

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot , Chief Executive Officer, President and Co-Founder, will present

Read More
Jan 04

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources

CAMBRIDGE, Mass. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President,

Read More